The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Catalytic Nanoradiosensitizers
In article number 2306328, Jiangfeng Du, Xiao Zhang, Gan Tian, and co‐workers engineer single‐component manganese tungstate (MnWO4) as a new kind of catalytic nanoradiosensitizer, which shows augmented Fenton‐like effect under X‐ray stimulation and enables the synergy of chemodynamic therapy and radiotherapy for efficient treatment of triple negative breast cancer, expanding...
Nanomedicine‐based synergy of chemodynamic therapy (CDT) and radiotherapy (RT) modulated by tumor microenvironment enables rapid tumor ablation, which holds great hope for the refractory and recurrent cancers, such as triple negative breast cancer (TNBC). The clinical translation of hafnium oxide (HfO2), commercially named as NBTXR3, has aroused new research focus on single‐component inorganic nanomedicines...